Formulation and characterization of Mirtazapine loaded mucoadhesive cubosomal in-situ gel for intranasal delivery

The optimized formulation exhibited 90.33% drug release which confirms that it exhibited superior drug release characteristic as compared to pure drug suspension. The optimized formulation was evaluated for nasal toxicity studies which assure its safety to nasal mucosal membrane. The <i>in-vivo</i> brain biodistribution study showed the Mirtazapine cubosomal in situ gel achieved higher brain concentrations compared to the oral suspension. The cubosomal in-situ gel of Mirtazapine seems to be a promising and safe approach for treatment of depression.